Your browser doesn't support javascript.
loading
The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study.
Zeng, Shaoqing; Chi, Jianhua; Liu, Jiahao; Jiao, Xiaofei; Liu, Xingyu; Yu, Yang; Li, Ruyuan; Huo, Yabing; Ma, Guanchen; Zhao, Yingjun; Wang, Li; Zhou, Qi; Zou, Dongling; Cheng, Xiaodong; Li, Qingshui; Wang, Jing; Yao, Shuzhong; Zhao, Weidong; Xia, Bairong; Chen, Youguo; Fan, Jiangtao; Wang, Wei; Hong, Li; Guo, Ruixia; Liu, Ziling; Gao, Yunong; Li, Jundong; Zhang, Bei; Yu, Jinjin; Hu, Ting; Zhang, Wei; Shan, Wanying; Peng, Zikun; Li, Ming; Xie, Xing; Ma, Ding; Gao, Qinglei.
  • Zeng S; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Chi J; Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liu J; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Jiao X; Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liu X; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yu Y; Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Li R; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Huo Y; Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Ma G; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhao Y; Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang L; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhou Q; Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zou D; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cheng X; Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Li Q; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang J; Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yao S; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhao W; Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Xia B; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Chen Y; Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Fan J; Department of Cancer Biology Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
  • Wang W; Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  • Hong L; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
  • Guo R; Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  • Liu Z; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
  • Gao Y; Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Li J; Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
  • Zhang B; Hunan Clinical Research Center in Gynecologic Cancer, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Yu J; Department of Gynecologic Cancer, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Hu T; Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Zhang W; Department of Gynecology and Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
  • Shan W; Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Peng Z; Department of Gynecology and Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
  • Li M; Department of Gynecology & Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Xie X; Department of Gynecology, Guangxi Medical University First Affiliated Hospital, Nanning, China.
  • Ma D; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Gao Q; Department of Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan, China.
BJOG ; 129 Suppl 2: 60-69, 2022 11.
Article en En | MEDLINE | ID: mdl-36485066
ABSTRACT

OBJECTIVE:

To produce high-quality, real-world evidence for oncologists by collating scattered gynaecologic oncology (GO) medical records in China.

DESIGN:

Retrospective study.

SETTING:

The National Union of Real-world Gynaecological Oncology Research and Patient Management Platform (NUWA platform). SAMPLE Patient-centred data pool.

METHODS:

The NUWA platform integrated inpatient/outpatient clinical, gene and follow-up data. Data of 11 456 patients with ovarian cancer (OC) were collected and processed using 91 345 electronic medical records. Structured and unstructured data were de-identified and re-collated into a patient-centred data pool using a predefined GO data model by technology-aided abstraction. MAIN OUTCOME

MEASURES:

Recent treatment pattern shifts towards precision medicine for OC in China.

RESULTS:

Thirteen first-tier hospitals across China participated in the NUWA platform up to 7 December 2021. In total, 3504 (30.59%) patients were followed up by a stand-alone patient management centre. The percentage of patients undergoing breast cancer gene (BRCA) mutation tests increased by approximately six-fold between 2017 and 2018. A similar trend was observed in the administration rate of poly(ADP-ribose) polymerase inhibitors as first-line treatment and second-line treatment after September 2018, when olaparib was approved for clinical use in China.

CONCLUSION:

The NUWA platform has great potential to facilitate clinical studies and support drug development, regulatory reviews and healthcare decision-making.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Pueblos del Este de Asia Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Pueblos del Este de Asia Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article